Keros Therapeutics
General Information | |
Business: |
We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. We are a leader in understanding the role of the Transforming Growth Factor-Beta, or TGF-ß, family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. We have leveraged this understanding and developed a discovery approach to generate large and small molecules to address diseases of these tissues. |
Industry: | PHARMACEUTICAL PREPARATIONS |
Employees: | 23 |
Founded: | 2015 |
Contact Information | |
Address | 99 Hayden Avenue, Suite 120, Building E, Lexington, MA 02421, US |
Phone Number | (617) 314-6297 |
Web Address | http://www.kerostx.com |
View Prospectus: | Keros Therapeutics |
Financial Information | |
Market Cap | $302.0mil |
Revenues | $0.01 mil (last 12 months) |
Net Income | $-14.1 mil (last 12 months) |
IPO Profile | |
Symbol | KROS |
Exchange | NASDAQ |
Shares (millions): | 6.0 |
Price range | $16.00 - $16.00 |
Est. $ Volume | $96.0 mil |
Manager / Joint Managers | Jefferies/ SVB Leerink/ Piper Sandler |
CO-Managers | H.C. Wainwright & Co. |
Expected To Trade: | 4/8/2020 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |